Cary, NC, United States
Cary, NC, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.marketwired.com

CARY, NC--(Marketwired - May 09, 2017) - Today, Chiesi USA announced the appointment of two key leadership roles as the company continues to focus on growth in the U.S. hospital and adjacent specialty product sector. Doug Baratta has been promoted to Vice President of Specialty and Corporate Accounts, and Donna White has been promoted to Vice President of Contracts and Compliance. "In today's ever-changing pharmaceutical landscape, Doug and Donna each bring a wealth of expertise to their new strategic roles," said Jon Zwinski, Senior Vice President of Sales, Chiesi USA. "Their unique contributions have positioned them to help us drive forward as we chart new territory in providing innovative solutions in cardiovascular therapeutics, neonatology and specialty care for patients." In Baratta's expanded role, he is responsible for key customer-facing operations including Chiesi USA's relationships with wholesalers, specialty pharmacies, customer service and inside sales. From this vantage, Baratta leverages strategic benefits across these functions to better support customers while delivering value to the business. He joined Chiesi USA in 2011, most recently serving as a Senior Director of Corporate Accounts. Baratta has a strong track record of sales and leadership in the pharmaceutical industry, having previously served at Brighton Pharmaceuticals, Victory Pharma and others over the past 25 years. White, who has been with Chiesi USA since 2004, most recently held the position of Senior Director of Contracts and Compliance. She leads two critical functions -- compliance and contracting -- and is embedded within the commercial team. White's leadership in compliance is recognized throughout the industry while her strategic view of contracting impacts the company's bottom line. White has nearly 20 years of experience in pharmaceuticals, holding previous positions with Cornerstone Therapeutics, Cephalon and Biovail. Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company's strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. For more information, visit www.chiesiusa.com.


Van Maanen M.A.,University of Amsterdam | Stoof S.P.,University of Amsterdam | LaRosa G.J.,Cornerstone Therapeutics | Vervoordeldonk M.J.,University of Amsterdam | Tak P.P.,University of Amsterdam
Annals of the Rheumatic Diseases | Year: 2010

Background: The α7 subunit of nicotinic acetylcholine receptors (α7nAChR) can negatively regulate the synthesis and release of proinflammatory cytokines by macrophages and fibroblast-like synoviocytes in vitro. In addition, stimulation of the α7nAChR can reduce the severity of arthritis in murine collagen-induced arthritis (CIA). Objective: To provide more insight into the role of the α7nAChR in the pathogenesis of arthritis by investigating the effect of the absence of α7nAChR in CIA in α7-deficient (α7nAChR-/-) compared with wild-type (WT) mice. Methods: CIA was induced in α7nAChR-/- and WT littermate mice at day 0 by immunisation with chicken collagen type II (cCII) followed by a booster injection with cCII on day 20. Mice were killed on day 44 or day 63 and arthritis activity as well as radiological and histological damage were scored. The effects on the immune response were evaluated by measurement of antigen-specific antibodies and cytokines, and evaluation of the effects on antigen-specific stimulated spleen cells. Results: In α7nAChR -/- mice a significant increase in the incidence and severity of arthritis as well as increased synovial inflammation and joint destruction were seen. Exacerbation of CIA was associated with elevated systemic proinflammatory cytokines and enhanced T-helper cell 1 (Th1)-cytokine and tumour necrosis factor α production by spleen cells. Moreover, a specific decrease in the collagen-specific 'Th1-associated' IgG2a response was seen, whereas IgG1 titres were unaffected. Conclusions: The results presented here indicate that immune cell function in a model of rheumatoid arthritis is regulated by the cholinergic system and, at least in part, mediated by the α7nAChR.


Patent
Cornerstone Therapeutics | Date: 2012-08-23

The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment.


Patent
Cornerstone Therapeutics | Date: 2011-03-23

Disclosed are novel piperazine derivatives that act as agonists of the 7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.


Patent
Cornerstone Therapeutics and Han | Date: 2015-12-30

The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment.


Patent
Cornerstone Therapeutics | Date: 2014-07-29

Disclosed are novel piperazine derivatives that act as agonists of the 7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.


Trademark
Cornerstone Therapeutics | Date: 2012-01-09

Pharmaceutical preparations for the treatment of cardiovascular disorders.


Trademark
Cornerstone Therapeutics | Date: 2012-01-09

Pharmaceutical preparations for the treatment of cardiovascular disorders.


Trademark
Cornerstone Therapeutics | Date: 2012-01-09

Pharmaceutical preparations for the treatment of cardiovascular disorders.


Loading Cornerstone Therapeutics collaborators
Loading Cornerstone Therapeutics collaborators